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Abstract
Introduction: Methotrexate (MTX) has been shown to modify infliximab pharmacokinetics in rheumatoid arthritis.
However, its combination with infliximab in the treatment of ankylosing spondylitis (AS) is not recommended. The
objective of this study was to examine the influence of MTX on infliximab exposure in patients with AS.
Methods: Patients with AS patients who had predominantly axial symptoms were randomised to receive infliximab
alone (infusions of 5 mg/kg at weeks 0, 2, 6, 12 and 18) or infliximab combined with MTX (10 mg/week). Infliximab
concentrations were measured before and 2 hours after each infusion and at 1, 3, 4, 5, 8, 10, 14 and 18 weeks. We
estimated individual cumulative area under the concentration versus time curves (AUC) for infliximab concentration
between baseline and week 18 (AUC0-18). Clinical and laboratory evaluations were performed at each visit. The Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) score was the primary end point for clinical response.
Results: Twenty-six patients were included (infliximab group: n = 12, infliximab + MTX group: n = 14), and 507
serum samples were available for measurement of infliximab concentration. The two groups did not differ with
regard to AUC0-18 or evolution of BASDAI scores and biomarkers of inflammation.
Conclusions: The combination of MTX and infliximab does not increase the exposure to infliximab over infliximab
alone in patients with AS.
Trial registration: ClinicalTrials.gov: NCT00507403
Introduction
Infliximab, a chimeric monoclonal antibody to TNF-a,
showed efficacy for ankylosing spondylitis (AS) in a ran-
domised, placebo-controlled trial in which 61.2% of the
patients were responders at 24 weeks [1]. Although
methotrexate (MTX) is often used for patients with pre-
dominantly peripheral AS and those with psoriatic
arthritis, the few attempts to treat predominantly axial
disease were disappointing. Haibel et al.[ 2 ]s t u d i e d2 0
patients with AS who received MTX 15 to 20 mg/week
subcutaneously and found no difference in Assessment
in Ankylosing Spondylitis 20% improvement criteria
(ASAS 20) scores before and 16 weeks after treatment.
Until now, MTX has been evaluated in only three small,
randomised, controlled trials [3-5], and a Cochrane
review [6] concluded that there was insufficient evidence
to support the use of MTX for AS with predominantly
axial symptoms.
Data comparing infliximab with and without MTX
treatment in AS are sparse and conflicting. Pérez-Guijo
et al. [7] found a greater reduction in Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) scores with
infliximab + MTX treatment than with infliximab alone,
whereas Breban et al. [8] found no statistically signifi-
cant difference between patients who did or did not
receive MTX in a subset of AS patients receiving treat-
ment with infliximab by an on-demand strategy. How-
ever, in the latter study, patients receiving MTX showed
a better response and fewer reactions to infusions than
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were not statistically significant [8]. Currently, regarding
TNF-a antagonist therapy for patients with AS or psor-
iatic arthritis, the French Society for Rheumatology
recommendations suggest that there is insufficient evi-
dence for concomitant disease-modifying antirheumatic
drugs improving the effectiveness of TNF-a antagonist
therapy [9].
To date, no study has used infliximab exposure as an
end point to compare treatment with the combination
of infliximab and MTX with infliximab alone in AS with
predominantly axial symptoms. Indeed, if such a combi-
nation increases exposure to infliximab, it should
improve response and may be recommended in clinical
practice. In the present study, we compared the indivi-
dual exposure to infliximab of AS patients with predo-
minantly axial symptoms receiving infliximab alone or
infliximab and MTX combined.
Materials and methods
Patients and study protocol
From January 2008 to April 2009, AS patients with pre-
dominantly axial symptoms were recruited to participate
in this two-centre, open-label, prospective, randomised
study comparing treatment with infliximab alone and
infliximab with MTX. All patients fulfilled the New York
revised criteria for AS [10]. Infliximab was given intrave-
nously (5 mg/kg) at weeks 0, 2, 6, 12 and 18 in accor-
dance with our guidelines [9]. MTX 10 mg was given
orally every week. After patients were randomised to a
treatment group, a total of 12 visits were scheduled at
each infliximab infusion and between infusions at 1, 3, 4,
5, 8, 10 and 14 weeks. Blood samples were collected
before and two hours after the end of each infusion and
at each visit. We estimated that we needed about 30
patients to compare infliximab exposure between the two
treatment groups. The study protocol was in compliance
with the Declaration of Helsinki, approved by the ethic
committee of Tours University Hospital and registered
(ClinicalTrials.gov ID: NCT00507403). All patients gave
their informed consent to participate in the study.
Clinical measurements
At each visit, patients were asked to complete a BASDAI
questionnaire and were classified as responders if their
B A S D A Is c o r e( o na1 0 - p o i n ts c a l e )a tw e e k1 8w a st w o
points lower than at baseline [9,11]. Treatment response
was also assessed according to the Assessment in Anky-
losing Spondylitis 20% improvement criteria (ASAS 20).
Serum infliximab and antibodies toward infliximab
concentrations
Analyses of serum infliximab and antibody toward
infliximab (ATI) concentrations were centralised in
Tours University Hospital. Infliximab serum concentra-
tion was measured in samples by using ELISA as
described previously [12]. Serum concentration of ATI
was measured by using a double-antigen ELISA on the
basis of capture by infliximab-coated microplates and
detection by peroxidase-conjugated infliximab. This
assay was standardised by the use of a mouse monoclo-
nal antibody against human immunoglobulin G. The
positive threshold of detection was 0.07 mg/L. Because
of the interference of circulating infliximab, only sera
with infliximab concentrations < 2 mg/L were tested.
Statistical analysis
Individual exposure to infliximab was estimated by the
cumulative area under the concentration versus time
curve between baseline and week 18 (AUC0-18) by popu-
lation pharmacokinetics modelling. The best description
of infliximab concentrations was obtained by use of a
two-compartment model with first-order distribution
and elimination constants. Characteristics at baseline
and the proportion of responders in each group were
compared by using nonparametric tests. The results are
presented in Table 1 as medians [range] unless other-
wise stated. Statistical analysis involved the use of R
2.7.2 software [13].
Results
We included 26 patients: 12 in the infliximab-only group
and 14 in the infliximab + MTX group. The patients’ char-
acteristics at baseline are given in Table 1. A total of 507
samples were available for measurement of serum inflixi-
mab concentrations. Individual AUC0-18 results for
Table 1 Baseline characteristics of 26 patients with
ankylosing spondylitis and predominantly axial
symptoms randomised to receive infliximab or infliximab
+ methotrexate
a
Characteristics Infliximab
(n = 12)
Infliximab +
MTX
(n = 14)
P
value
Sex, men/women (n/%) 9/3 (75/25) 11/3 (79/21) 0.8
Median age, years 42.5 [27 to
59]
45.5 [29 to 55] 0.3
Median disease duration, years 4.0 [0 to 28] 4.5 [1 to 19] 0.9
Human leukocyte antigen B27
+,
n (%)
9 (75) 10 (71) 0.8
NSAIDs, n (%) 8 (67) 12 (86) 0.5
Previous TNF-a, n (%) 2 (17) 2 (14) 1.0
Median BASDAI score 5.8 [3.9 to
8.4]
7.0 [5.0 to 8.2] 0.2
Median C-reactive protein, mg/L 3.6 [0.5 to
18.0]
2.7 [0.5 to
31.2]
0.5
a MTX: methotrexate; BASDAI: Bath Ankylosing Spondylitis Disease Activity
Index; NSAIDs: nonsteroidal anti-inflammatory drugs. Results are given as
medians [range] unless otherwise indicated.
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groups did not differ in terms of AUC0-18 results. The
median AUC0-18 value was 165,502 mg/hour/L [50,569 to
203,782] for the infliximab-only group and 164,222 mg/
hour/L [102,165 to 295,858] for the infliximab + MTX
group. Likewise, MTX had no effect on estimated pharma-
cokinetics parameters (data not shown). Positivity for ATI
was detected in only one patient, a 43-year-old woman in
the infliximab-only group who was negative for human
leukocyte antigen B27. At weeks 4, 5 and 6, her infliximab
concentrations were < 1 mg/L and ATIs were detected at
weeks 12 and 18. Her exposure to infliximab was low
(AUC0-18 = 50,569 mg/hour/L), and the infliximab elimi-
nation clearance was twice that of ATI-negative patients
(data not shown).
The two groups did not differ with regard to clinical
activity or inflammation. Responses between the two
groups were similar at week 18 (Additional file 1).
Responders displayed a rapid decrease in BASDAI score
compared with nonresponders, with a statistically signif-
icant difference observed at week 6 and thereafter
(Additional file 2). The proportions of previous anti-
TNF-a and current NSAIDs were similar in both
responders and nonresponders.
Discussion
We did not observe any influence of MTX on infliximab
exposure in AS patients with predominantly axial
symptoms. Our study is the first to answer the question
whether MTX may affect infliximab pharmacokinetics in
AS with predominantly axial symptoms. Previously, Kri-
siek et al. [14] analysed blood samples from AS patients
receiving treatment with infliximab by an on-demand
strategy with or without MTX. In their post hoc analysis
involving 34 patients receiving MTX and 42 patients not
receiving MTX, infliximab concentrations were mea-
s u r e da tw e e k s2a n d6a f t e rt r e a t m e n t .T h ea u t h o r s
found no significant difference in infliximab levels
between the two groups. Our results are in agreement
w i t ht h e s ep r e v i o u s l yp u b l i s h e dr e s u l t sa n dp r o v i d ea
precise estimation of the drug exposure with repeated
and prolonged measurement of infliximab.
We found no difference between treatment groups
with regard to change in BASDAI scores or ASAS 20
criteria, findings which are in agreement with results
from previous controlled trials [3-5]. Although clinical
outcome was not our objective, our results do not argue
for a clinical benefit of adding MTX to infliximab treat-
ment (5 mg/kg/infusion) for AS with predominantly
axial symptoms. Patients who were responders at week
18 showed a rapid decrease in BASDAI scores, which
suggests that an early decrease in BASDAI score may
predict a response later on. By contrast, a patient who
has not responded at 6 weeks after initiation seems
likely to be a primary nonresponder.
The MTX dosage we used, 10 mg/week orally, was in
agreement with the recommendation by an expert opi-
nion of a broad international panel of rheumatologists
[15]. A subcutaneous route or higher dosage than 10
mg/week would not likely have changed our results,
because a previous study found no clinical response in
patients with AS receiving MTX 15 to 20 mg/week sub-
cutaneously [2].
We observed an important variability in infliximab
exposure in both groups of patients. This variability has
been reported in previous studies in which trough con-
centration was measured [14,16]. Our study provides a
more precise characterisation of this variability and con-
firms that exposure to treatment differs considerably
among individuals.
We found that one patient was positive for ATI. Of
note, this patient did not receive MTX, and this finding
raises the question of the hypothetical role of immuno-
suppressive agents in preventing immunisation as
reported in rheumatoid arthritis (RA) and Crohn’sd i s -
ease [17-19]. Because of the small number of partici-
pants and the relatively short duration of the study, no
conclusion can be drawn regarding the potential role of
MTX in reducing immunogenicity in AS.
Our results differ from those of Maini et al. [17], who
found that MTX increased infliximab concentrations in
RA. In RA, disease activity at baseline was found to be
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Figure 1 Area under the concentration curve versus the time
curve for serum infliximab concentration between baseline
and week 18 (AUC0-18) for patients with ankylosing spondylitis
who had predominantly axial symptoms and were receiving
infliximab or infliximab + methotrexate (MTX) treatment. The
patient with anti-infliximab antibodies is shown as an open circle.
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tion at 6 weeks after initiation of treatment [20,21]. This
phenomenon may be explained by targeted mediated-
drug disposition and high levels of TNF-a (which corre-
sponds to antigenic burden) binding infliximab, which
influence its pharmacokinetics. MTX is effective as
monotherapy in patients with RA by decreasing TNF-a
levels, which in turn increase infliximab concentrations
[17]. That MTX did not improve infliximab exposure in
our study patients with AS who had predominantly axial
symptoms may reflect the fact that TNF-a antigenic
burden is lower in AS than in RA.
Conclusion
MTX seems to have no significant effect on infliximab
pharmacokinetics in AS with predominantly axial symp-
toms. These results do not argue for adding MTX to
infliximab therapy in this condition.
Additional material
Additional file 1: Figure S1. Percentage of responders according to
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ( > 2-
point reduction between baseline and week 18) and Assessment in
Ankylosing Spondylitis 20% improvement criteria (ASAS 20) for patients
with ankylosing spondylitis who had predominantly axial symptoms and
were receiving infliximab or infliximab + methotrexate (MTX) treatment.
Additional file 2: Figure S2. Changes in BASDAI scores for treatment
responders (filled circles; n = 12) and nonresponders (open circles; n =
14) receiving infliximab alone or infliximab + methotrexate treatment.
†P
< 0.05.
‡P < 0.01.
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